The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.
Source: BioPharma Dive
You may also like
Beyond Boston: Unlikely cities stake biotech claims
Vera Therapeutics wins FDA nod for closely watched...
Novartis to pay $1.1B upfront for UK biotech Myricx to...
Genentech lays off 103 alongside gRED rethink, pens...
Scribe notes down IPO ambition to fund lipid-lowering...
Exact Imaging boosts U.S. commercial team for next-gen...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.